Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Amer Sports Inc (AS) Price & Performance

Abeona Therapeutics Inc
Amer Sports Inc

Price performance

Price movement over the last 24 hours

Key statistics

Abeona Therapeutics Inc vs Amer Sports Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Amer Sports Inc trades at $33.09 (market cap $19.80B). The key difference: Amer Sports Inc is far larger — about 53× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.

ABEOAS
Market Cap
$373.32M$19.80B
Sector
HealthTechnology
52-Week High
$7.23$41.96
52-Week Low
$4.17$29.54
Enterprise Value
$228.22M$20.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

Amer Sports Inc

Amer Sports (AS) trades at $34.84, down 0.6% on the day, with a neutral technical outlook. The company reported strong Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion. Analyst sentiment is overwhelmingly positive, with 12 of 14 analysts rating it a Buy and a consensus price target of $56.00, implying significant upside. Operating cash flow remains robust at $729.80 million for 2025.

The outlook is favorable given consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 43.54) and dependence on the Arc'teryx brand's sustained momentum. The stock presents a growth opportunity if execution continues, though premium valuation requires careful monitoring of margin trends and competitive pressures.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Amer Sports Inc

Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.

Read more on AS